COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

National Weight-Loss Study Open At Moores UCSD Cancer Center

 

April 10, 2007  |  

Nutrition experts at the Moores UCSD Cancer Center and Scripps Clinic in Del Mar are seeking obese men and women to participate in a research study for weight loss employing an investigational combination drug therapy and behavioral modification. Study participants will receive at no cost medical evaluations, individualized diet and exercise programs, weekly nutritional and lifestyle group sessions, and the investigational study drugs or placebo.

The UCSD and Scripps collaboration represents one of nine study sites in the U.S. The study drugs have been shown to be safe and effective in preliminary clinical trials and are FDA approved for other conditions but not yet for weight loss.

To be eligible for this study, an individual must be obese, a non-smoker for at least six months, between 18 and 65 years of age, non-diabetic and in overall good health.

For further information, call the clinical research coordinator at UCSD Moores Cancer Center, 858-822-2779.

# # #

Media Contact:  Nancy Stringer,  619-543-6163, nstringer@ucsd.edu




Media Contact

Share This Article


Related News

7/26/2021
UC San Diego Health, the region’s only academic health system, is ranked #1 in San Diego and #5 in California, placing it among the nation’s best hospitals, according to the 2021-2022 U.S. News & Worl ...
7/23/2021
Senate President Pro Tempore Toni Atkins visited UC San Diego Medical Center today to recognize a $30 million allocation in the 2021-2022 California state budget that will support the redevelopment of ...
7/16/2021
Researchers at UC San Diego School of Medicine and Rady Children’s Institute for Genomic Medicine have produced a stem cell model that demonstrates a potential route of entry of SARS-CoV-2, the virus ...
7/15/2021
Using anonymized medical records from a national registry, UC San Diego researchers confirm earlier findings that statins may substantially minimize adverse outcomes from SARS-CoV-2 infection.



Follow Us